Accessibility Menu
Acura Pharmaceuticals logo

Acura Pharmaceuticals(OTC) ACUR

Market Cap$6.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1986)-100%
5 Year-100%
1 Year-80%
1 Month-89%
$0.00
-66.67%
-0.00Today
Acura Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-03
Acura Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-24
1 month-88.89%USD 0.002026-06-25
3 month-80%USD 0.002026-05-04
Year to date-80%USD 0.002025-12-31
1 year-80%USD 0.002025-07-31
3 year-75%USD 0.002023-08-03
5 year-99.98%USD 0.532021-08-04
Since inception-100%USD 73.701986-03-17

Acura Pharmaceuticals Financials at a Glance

Market Cap

$6.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.56M

Net Income (TTM)

-$879.00K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

29.41 (High)

Price

$0.00

Volume

7

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Feb 26, 2025

ACUR News

3 Companies That Put the "Tech" in "Biotech"

Keith SpeightsMay 16, 2013

Whoa! What Just Happened to My Stock?

Rich DupreyApr 18, 2013

CAPScall of the Week: Acura Pharmaceuticals

Sean WilliamsFeb 26, 2013

3 Stocks to Get on Your Watchlist

Sean WilliamsFeb 13, 2013

This Week in Biotech

Sean WilliamsDec 15, 2012

Why Acura Is Poised to Pull Back

BRIAN PACAMPARADec 11, 2012

Acura Investors: Why Shares Popped 70%

Dave WilliamsonDec 10, 2012

The Dow Catches Its Breath

Dave WilliamsonJul 30, 2012
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a drug delivery innovator focused on developing technologies that enhance medication safety. The company offers a range of products, including prescription narcotics and over-the-counter medications, while actively advancing additional opioid products.

Products and Services
  • Oxaydo tablets for managing moderate-to-severe pain
  • Nexafed line for cold, sinus, and allergy relief
  • Six additional opioid products in development
Growth Outlook
  • Strategic partnerships with Egalet for global commercialization
  • Advancements in opioid product formulations to meet market needs
  • Focus on proprietary LIMITx technology for new product development
Financial Highlights
  • Recent quarterly revenue of $36,000, showing potential for growth
  • Trailing twelve months (TTM) gross profit margin at 94.24%
  • Current ratio of 0.72 indicates liquidity management challenges
Acura Pharmaceuticals operates in the healthcare sector, specifically within the drug manufacturing industry. The company is headquartered in Palatine, Illinois, and has been in operation since 1935. With a market capitalization of approximately $6,600, the company is positioned to leverage its innovative drug delivery technologies to enhance patient safety and efficacy. The strategic collaborations with Egalet and Abuse Deterrent Pharma highlight the company's commitment to expanding its product offerings and market reach. Despite recent financial challenges, the high gross profit margin indicates strong potential for profitability as the company continues to develop and market its products.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9

CEO

Robert B. Jones, MBA

Website

www.acurapharm.com

Headquarters

Palatine, IL 60067, US

ACUR Financials

Key Financial Metrics (TTM)

Gross Margin

94.24%

Operating Margin

-77.67%

Net Income Margin

-56.24%

Return on Equity

30.77%

Return on Capital

-321.16%

Return on Assets

-102.21%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

66.00M

Volume

7

Avg. Volume

325.413

Financials (TTM)

Gross Profit

$1.00M

Operating Income

-$1.21M

EBITDA

-$606.00K

Operating Cash Flow

-$742.00K

Capital Expenditure

$0.00

Free Cash Flow

-$742.00K

Cash & ST Invst.

$65.00K

Total Debt

$200.00K

Acura Pharmaceuticals Performance Analysis

Acura Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,563,000N/A
Acura Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-03-31-10.3%
Q22021-06-30-4.8%
Q32021-09-30-56.0%
Q42021-12-31-86.7%
Acura Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.02N/A
Acura Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-03-319.1%
Q22021-06-30N/A
Q32021-09-3065.0%
Q42021-12-31111.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2021YOY CHG

Revenue

$36.00K

-95.0%

Gross Profit

$9.00K

-98.7%

Gross Margin

25.00%

N/A

Market Cap

$6.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$733.33

N/A

Employees

9

N/A

Net Income

$29.00K

+111.9%

EBITDA

$47.00K

+142.0%

Quarterly Fundamentals

Name
Q4 2021YOY CHG

Total Cash

$65.00K

-84.3%

Total Debt

$200.00K

-96.8%

Accounts Receivable

$158.00K

-74.8%

Inventory

$0.00

N/A

Long Term Debt

$167.00K

+59.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.02%

N/A

Return on Invested Capital

-3.52%

N/A

Free Cash Flow

-$426.00K

-432.5%

Operating Cash Flow

-$426.00K

-432.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNBXCNBX Pharmaceuticals Inc.
$0.00+0.00%
GNLKQGeneLink, Inc.
$0.00+0.00%
MRRCFWayland Group Corp.
$0.00+0.00%
AZFLAmazonas Florestal, Ltd
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About ACUR

What is the current price of Acura Pharmaceuticals?

Acura Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Acura Pharmaceuticals?

Over the past 52 weeks, Acura Pharmaceuticals has traded between $0.00 and $0.01.

How much debt does Acura Pharmaceuticals have?

As of the most recent reporting period, Acura Pharmaceuticals reported total debt of $200.00K.

How much cash does Acura Pharmaceuticals have on hand?

Acura Pharmaceuticals reported $65.00K in cash and cash equivalents in its most recent financial results.

What is Acura Pharmaceuticals’s dividend yield?

Acura Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services